Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





PHORATE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 298-02-2; **Chemical Formula:** C7H17O2PS3
Previously, OSHA had no limit for phorate. The ACGIH has limits of 0.05 mg/m3 as an 8-hour TWA and 0.2 mg/m3 as a STEL for phorate, with a skin notation. The proposed PELs were 0.05 mg/m3 as an 8-hour TWA PEL, with a STEL of 0.2 mg/m3 and a skin notation; NIOSH concurs with these limits (Ex. 8-47, Table N1), which are established in the final rule. Phorate is an organophosphorus cholinesterase inhibitor that takes the form of a clear liquid and is used as an insecticide.
Phorate is a highly toxic compound in animals. Rats exposed to daily doses of phorate showed effects above 0.15 mg/kg/day but no effects below this level. The no-effect level in dogs is between 0.01 and 0.05 mg/kg/day (Gaines 1969/Ex. 1-320). The dermal LD(50) in male rats is 6.2 mg/kg and, for female rats, 25 mg/kg.
The final rule’s limits of 0.05 mg/m3 as an 8-hour TWA, supplemented by a STEL of 0.2 mg/m3 and a skin notation, are based on calculations that the no-effect level in humans would lie in the range between 0.21 and 0.7 mg/day, and that use of an appropriate safety factor would suggest an 8-hour limit of 0.05 mg/m3, with a STEL of 0.2 mg/m3, to ensure against excursions greatly in excess of the TWA limit. OSHA received no comments on phorate except those from NIOSH.
OSHA finds that these limits will protect workers exposed to phorate against cholinesterase inhibition and its associated effects, which include respiratory symptoms, nausea, confusion, and vomiting. The Agency concludes that, in the absence of any OSHA limit, phorate-exposed employees were formerly at significant risk of experiencing such effects and that establishing a PEL, STEL, and skin notation will substantially reduce these risks. OSHA finds that cholinesterase inhibition and its symptoms clearly constitute material impairments of health.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue